Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
Trending
- Genomic and transcriptomic landscape of spread through air spaces in stage 1 lung adenocarcinoma
- I was a professional singer – but cancer took my voice box
- Immunogenic cell death as a mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors
- Autophagy inhibition sensitizes radiotherapy responses in high-grade mutant IDH1 glioma
- Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL
- FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
- Immune regulation includes an effector arm: therapeutic implications of phase III IDO/PD-L1 vaccination in melanoma
- Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer

